Stop feeding cancer: Pro-inflammatory role of visceral adiposity in liver cancer

Cytokine

Volumn 64, Issue 3, 2013, Pages 626-637

  Zhao, Jun ^a   Lawless, Matthew W ^a  

^a MATER MISERICORDIAE UNIVERSITY HOSPITAL   (Ireland)

Author keywords

Endoplasmic reticulum (ER) stress; Inflammation; Liver cancer (HCC); Visceral adiposity

Indexed keywords

ADIPOCYTOKINE; C REACTIVE PROTEIN; FATTY ACID; HISTONE DEACETYLASE INHIBITOR; HYPOXIA INDUCIBLE FACTOR 1; I KAPPA B KINASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INSULIN; INTERLEUKIN 10; INTERLEUKIN 6; LEPTIN; MICRORNA; MITOGEN ACTIVATED PROTEIN KINASE; MONOCYTE CHEMOTACTIC PROTEIN 1; PANOBINOSTAT; PROTEIN KINASE B; REACTIVE OXYGEN METABOLITE; RETINOL BINDING PROTEIN 4; SNX 5422; SOMATOMEDIN B; SOMATOMEDIN BINDING PROTEIN; SOMATOMEDIN C; SORAFENIB; STAT3 PROTEIN; STRESS ACTIVATED PROTEIN KINASE; SUPPRESSOR OF CYTOKINE SIGNALING 3; TOLL LIKE RECEPTOR; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN;

ADIPOCYTE; ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER SUSCEPTIBILITY; CARCINOGENESIS; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CELLULAR STRESS RESPONSE; CHRONIC INFLAMMATION; CYTOKINE RELEASE; DISEASE ASSOCIATION; ENDOPLASMIC RETICULUM STRESS; HEPATITIS; HUMAN; HYPOXIA; IMMUNOREGULATION; INSULIN RESISTANCE; INTRAABDOMINAL FAT; LIPID STORAGE; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER FUNCTION; MACROPHAGE; MOLECULARLY TARGETED THERAPY; NATURAL KILLER CELL; NEUTROPHIL CHEMOTAXIS; NONALCOHOLIC FATTY LIVER; OBESITY; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; UNFOLDED PROTEIN RESPONSE;

ENDOPLASMIC RETICULUM (ER) STRESS; INFLAMMATION; LIVER CANCER (HCC); VISCERAL ADIPOSITY;

ADIPOSITY; CARCINOMA, HEPATOCELLULAR; HUMANS; INTERLEUKIN-6; INTRA-ABDOMINAL FAT; LIVER; LIVER NEOPLASMS; MODELS, BIOLOGICAL; OBESITY; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84886949542     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2013.09.009     Document Type: Review

References (191)

1. Bosch F.X., Ribes J., Diaz M., Cleries R. Primary liver cancer: worldwide incidence and trends. Gastroenterology 2004, 127(5 Suppl. 1):S5-S16.
2. Farazi P.A., DePinho R.A. Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev Cancer 2006, 6:674-687.
3. de Martel C., Ferlay J., Franceschi S., Vignat J., Bray F., Forman D., et al. Global burden of cancers attributable to infections in 2008: a review and synthetic analysis. Lancet Oncol 2012, 13(5):607-615.
4. Wolin K.Y., Carson K., Colditz G.A. Obesity and cancer. Oncologist 2010, 15:556-565.
5. Starley B.Q., Calcagno C.J., Harrison S.A. Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection. Hepatology 2010, 51(5):1820-1832.
6. Calle E.E., Rodriguez C., Walker-Thurmond K., Thun M.J. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of US adults. N Engl J Med 2003, 348:1625-1638.
7. Hu K.Q., Kyulo N.L., Esrailian E., Thompson K., Chase R., Hillebrand D.J., et al. Overweight and obesity, hepatic steatosis, and progression of chronic hepatitis C: a retrospective study on a large cohort of patients in the United States. J Hepatol 2004, 40(1):147-154.
8. Chang T.Y., Chen J.D. Fatty liver and metabolic syndrome in nonabdominally obese Taiwanese adults. Asia Pac J Public Health 2012, 24(3):472-479.
9. Petta S., Amato M.C., Di Marco V., Camma C., Pizzolanti G., Barcellona M.R., et al. Visceral adiposity index is associated with significant fibrosis in patients with non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2012, 35(2):238-247.
10. Ohki T., Tateishi R., Shiina S., Goto E., Sato T., Nakagawa H., et al. Visceral fat accumulation is an independent risk factor for hepatocellular carcinoma recurrence after curative treatment in patients with suspected NASH. Gut 2009, 58(6):839-844.
11. Schlesinger S., Aleksandrova K., Pischon T., Fedirko V., Jenab M., Trepo E., et al. Abdonimal obesity, weight gain during adulthood and risk factor of liver and biliary tract cancer in a European cohort. Int J Cancer 2013, 132(3):645-657.
12. Colotta F., Allavena P., Sica A., Garlanda C., Mantovani A. Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis 2009, 30(7):1073-1081.
13. Waxler S.H., Tabar P. Appearance of hepatomas in obese C3H male mice. Stanford Med Bull 1953, 11(4):272-273.
14. Chen Y., Wang X., Wang J., Yan Z., Luo J. Excess body weight and the risk of primary liver cancer: an updated meta-analysis of prospective studies. Eur J Cancer 2012, 48(14):2137-2145.
15. Kershaw E.E., Flier J.S. Adipose tissue as an endocrine organ. J Clin Endocrinol Metab 2004, 89:2548-2556.
16. Ahima R.S. Adipose tissue as an endocrine organ. Obesity (Silver Spring) 2006, (Suppl. 5):242S-249S.
17. Klein S. The case of visceral fat: argument for the defence. J Clin Invest 2004, 113(11):1530-1532.
18. Paschos P., Paletas K. Nonalcoholic fatty liver disease and metabolic syndrome. Hippokratia 2009, 13(1):9-19.
19. Vongsuvanh R., George J., Qiao L., van der Poorten D. Visceral adiposity in gastrointestinal and hepatic carcinogenesis. Cancer Lett 2013, 330(1):1-10.
20. Schapira D.V., Clark R.A., Wolff P.A., Jarrett A.R., Kumar N.B., Aziz N.M. Visceral obesity and breast cancer risk. Cancer 1994, 74:632-639.
21. Donohoe C.L., Doyle S.L., McGarrigle S., Cathcart M.C., Daly E., O'Grady A., et al. Role of the insulin-like growth factor 1 axis and visceral adiposity in oesophageal adenocarcinoma. Br J Surg 2012, 99(3):387-396.
22. Lysaght J., van der Stok E.P., Allott E.H., Casey R., Donohoe C.L., Howard J.M., et al. Pro-inflammatory and tumour proliferative properties of excess visceral adipose tissue. Cancer Lett 2011, 312(1):62-72.
23. Nishimura S., Manabe I., Nagasaki M., Eto K., Yamashita H., Ohsugi M., et al. CD8+ effector T cells contribute to macrophage recruitment and adipose tissue inflammation in obesity. Nat Med 2009, 15(8):914-920.
24. Ohmura K., Ishimori N., Ohmura Y., Tokuhara S., Nozawa A., Horii S., et al. Natural killer T cells are involved in adipose tissues inflammation and glucose intolerance in diet-induced obese mice. Arterioscler Thromb Vasc Biol 2010, 30:193-199.
25. Cancello R., Tordjman J., Poitou C., Guilhem G., Bouillot J.L., Hugol D., et al. Increased infiltration of macrophages in omental adipose tissue is associated with marked hepatic lesions in morbid human obesity. Diabetes 2006, 55:1554-1561.
26. Villaret A., Galitzky J., Decaunes P., Esteve D., Marques M.A., Sengenes C., et al. Adipose tissue endothelial cells from obese human subjects: differences among depots in angiogenic, metabolic and inflammatory gene expression and cellular senescence. Diabetes 2010, 59:2755-2763.
27. Hernandez-Morante J.J., Milagro F., Gabaldon J.A., Martinez J.A., Zamora S., Garaulet M. Effect of DHEA-sulfate on adiponectin gene expression in adipose tissue from different fat depots in morbidly obese humans. Eur J Endocrinol 2006, 155:593-600.
28. Filipowicz W., Bhattacharyya S.N., Sonenberg N. Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight?. Nat Rev Genet 2008, 9(2):102-114.
29. Ruan K., Fang X., Ouyang G. MicroRNAs: novel regulators in the hallmarks of human cancer. Cancer Lett 2009, 285(2):116-126.
30. Giordano S., Columbano A. MicroRNAs: new tools for diagnosis, prognosis, and therapy in hepatocellular carcinoma?. Hepatology 2013, 57(2):840-847.
31. Estep M., Armistead D., Hossain N., Elarainy H., Goodman Z., Baranova A., et al. Differential expression of miRNAs in the visceral adipose tissue of patients with non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2010, 32(3):487-497.
32. Wei RR, Huang GL, Zhang MY, Li BK, Zhang HZ, Shi M, et al. Clinical significance and prognostic value of microRNA expression signatures in hepatocellular carcinoma. Clin Cancer Res 2013;19(17):4780-91.
33. Greene CM, Varley R, Lawless MW. MicroRNA and liver cancer associated iron overload: therapeutic targets unravelled. World J Gastroenterol 2013;19(32):5212-26.
34. Hsu S.H., Wang B., Kota J., Yu J., Costinean S., Kutay H., et al. Essential metabolic, anti-inflammatory, and anti-tumorigenic functions of miR-122 in liver. J Clin Invest 2012, 122(8):2871-2883.
35. Xu Y., Xia F., Ma L., Shan J., Shen J., Yang Z., et al. MicroRNA-122 sensitizes HCC cancer cells to adriamycin and vincristine through modulating expression of MDR and inducing cell cycle arrest. Cancer Lett 2011, 10(2):160-169.
36. Li A., Qian J., He J., Zhang Q., Zhai A., Song W., et al. Modulation of miR-122 expression affects the interferon response in human hepatoma cells. Mol Med Rep 2013, 7(2):585-590.
37. Kambara H., Fukuhara T., Shiokawa M., Ono C., Ohara Y., Kamitani W., et al. Establishment of a novel permissive cell line for the propagation of hepatitis C virus by expression of microRNA miR122. J Virol 2012, 86(3):1382-1393.
38. Parekh S., Anania F.A. Abnormal lipid and glucose metabolism in obesity: implications for non-alcoholic fatty liver disease. Gastroenterology 2007, 132:2191-2207.
39. Kim C.H., Younossi Z.M. Nonalcoholic fatty liver disease: a manifestation of the metabolic syndrome. Cleveland Clin J Med 2008, 75(10):721-728.
40. Duan X.Y., Qiao L., Fan J.G. Clinical features of non-alcoholic fatty liver disease-associated hepatocellular carcinoma. Hepatobilliary Pancreat Dis Int 2012, 11(1):18-27.
41. Adams L.A., Lymp J.F., St Sauver J., Sanderson S.O., Lindor K.D., Feldstein A., et al. The natural history of non-alcoholic fatty liver disease: a population-based cohort study. Gastroenterology 2005, 129:113-121.
42. Jain D., Nayak N.C., Saigal S. Hepatocellular carcinoma in non-alcoholic fatty liver cirrhosis and alcoholic cirrhosis: risk factor analysis in liver transplant recipients. Eur J Gastroenterol Hepatol 2012, 24(7):840-848.
43. Donnelly K.L., Smith C.I., Schwarzenberg S.J., Jessurun J., Boldt M.D., Parks E.J. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with non-alcoholic fatty liver disease. J Clin Invest 2005, 115:1343-1351.
44. O'Connell J., Lynch L., Fatwood T.J., Kwasnik A., Nolan N., Geoghegan J., et al. The relationship of omental and subcutaneous adipocyte size to metabolic disease in severe obesity. PloS ONE 2010, 5(4):e9997. 10.1371/journal.pone.0009997.
45. Utzschneider K.M., Kahn S.E. The role of insulin resistance in non-alcoholic fatty liver disease. J Clin Endocrinol Metab 2006, 91(12):4753-4761.
46. Piquet A.C., Stroka D., Zimmermann A., Dufour J.F. Hypoxia aggravates non-alcoholic steatohepatitis in mice lacking hepatocellular PTEN. Clin Sci (Lond) 2009, 118(6):401-410.
47. Fartoux L., Poujol-Robert A., Guechot J., Wendum D., Poupon R., Serfaty L. Insulin resistance is a cause of steatosis and fibrosis progression in chronic hepatitis C. Gut 2005, 54(7):1003-1008.
48. Conover C.A., Lee P.D., Kanaley J.A., Clarkson J.T., Jensen M.D. Insulin regulation of insulin-like growth factor binding protein-1 in obese and nonobese humans. J Clin Endocrinol Metab 1992, 74(6):1355-1360.
49. Sandhu M.S., Dunger D.B., Giovannucci E.L. Insulin, insulin-like growth factor-1 (IGF-1), IGF binding proteins, their biological interactions and colorectal cancer. J Natl Cancer Inst 2002, 94(13):972-980.
50. Bonefeld K., Moller S. Insulin-like growth factor-1 and the liver. Liver Int 2011, 31(7):911-919.
51. Shao Y.Y., Huang C., Lin S.D., Hsu C.H., Cheng A.L. Serum insulin-like growth factor-1 levels predict outcomes of patients with advanced hepatocellular carcinoma receiving antiangiogenic therapy. Clin Cancer Res 2012, 18(14):3992-3997.
52. Li X., Nong Z., Ekstrom C., Larsson E., Nordlinder H., Hofmann W.J., et al. Disrupted IGF2 promoter control by silencing of promoter P1 in human hepatocellular carcinoma. Cancer Res 1997, 57:2048-2054.
53. Scharf J.G., Dombrowski F., Ramadori G. The IGF axis and hepatocarcinogenesis. Mol Pathol 2001, 54(3):138-144.
54. Yamaguchi M., Kamimura S., Takada J., Iwata K., Lida T., Kobayashi K., et al. Case report: insulin-like growth factor II expression in hepatocellular carcinoma with alcoholic liver fibrosis accompanied by hypoglycaemia. J Gastroenterol Hepatol 1998, 13(1):47-51.
55. Ishida S., Noda M., Kuzuya N., Kubo F., Yamada S., Yamanaka T., et al. Big insulin-like growth factor II-producing hepatocellular carcinoma associated with hypoglycaemia. Int Med 1995, 34(12):1201-1206.
56. Dowman J.K., Tomlinson J.W., Newsome P.N. Pathogenesis of non-alcoholic fatty liver disease. Q J Med 2010, 103:71-83.
57. Feldstein A.E., Werneburg N.W., Canbay A., Guicciardi M.E., Bronk S.F., Rydzewski R., et al. Free fatty acids promote hepatic lipotoxicity by stimulating TNF-alpha expression via a lysosomal pathway. Hepatology 2004, 40:185-194.
58. Schaffer J.E. Lipotoxicity: when tissues overeat. Curr Opin Lipidol 2003, 14:281-287.
59. Wood I.S., Heredia F.P., Want B., Trayhurn P. Cellular hypoxia and adipose tissue dysfunction in obesity. Proc Nutr Soc 2009, 68:370-377.
60. Park E.J., Lee J.H., Yu G.Y., He G., Ali S.R., Holzer R.G., et al. Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression. Cell 2010, 140(2):197-208.
61. Nakagawa H., Maeda S. Inflammation and stress-related signalling pathways in hepatocarcinogenesis. World J Gastroenterol 2012, 18(31):4071-4081.
62. Yu R., Kim C.S., Kwon B.S., Kawada T. Mesenteric adipose tissue-derived monocyte chemoattractant protein-1 plays a crucial role in adipose tissue macrophage migration and activation in obese mice. Obesity (Silver Spring) 2006, 14(8):1353-1362.
63. Batra A., Siegmund B. The role of visceral fat. Dig Dis 2012, 30(1):70-74.
64. Michaud A., Drolet R., Noel S., Paris G., Tchernof A. Visceral fat accumulation is an indicator of adipose tissue macrophage infiltration in women. Metabolism 2012, 61(5):689-698.
65. Yoshimoto S., Loo T.M., Atarashi K., Kanda H., Sato S., Oyadomari S., et al. Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome. Nature 2013, 499:97-101.
66. Zhang Y., Proenca R., Maffei M., Barone M., Leopold L., Friedman J.M. Positional cloning of the mouse obese gene and its human homologue. Nature 1994, 372:425-432.
67. Friedman J.M., Halaas J.L. Leptin and the regulation of body weight in mammals. Nature 1998, 395:763-770.
68. Franckhauser S., Munoz S., Elias I., Ferre T., Bosch F. Adipose overexpression of phosphoenolpyruvate carboxykinase leads to high susceptibility to diet-induced insulin resistance and obesity. Diabetes 2006, 55(2):273-280.
69. Stattin P., Lukanova A., Biessy C., Soderberg S., Palmgvist R., Kaaks R., et al. Obesity and colon cancer: does leptin provide a link?. Int J Cancer 2004, 109:149-152.
70. Garofalo C., Koda M., Cascio S., Sulkowska M., Kanczuga-Koda L., Golaszewska J., et al. Increased expression of leptin and the leptin receptor as a marker of breast cancer progression: possible role of obesity-related stimuli. Clin Cancer Res 2006, 12(5):1447-1453.
71. Ikejima K., Honda H., Yoshikawa M., Hirose M., Kitamura T., Takei Y., et al. Leptin augments inflammatory and profibrogenic responses in the murine liver induced by hepatotoxic chemicals. Hepatology 2001, 34:288-297.
72. Tsochatzis E., Papatheodoridis G.V., Hadziyannis E., Georgiou A., Kafiri G., Tiniakos D.G., et al. Serum adipokine levels in chronic liver diseases: association of resistin levels with fibrosis severity. Scand J Gastroenterol 2008, 43(9):1128-1136.
73. Wang J., Obici S., Morgan K., Barzilai N., Feng Z., Rossetti L. Overfeeding rapidly induces leptin and insulin resistance. Diabetes 2001, 50(12):2786-2791.
74. Segal K.R., Landt M., Klein S. Relationship between insulin sensitivity and plasma leptin concentration in lean and obese men. Diabetes 1996, 45(7):988-991.
75. Zimmet P., Hodge A., Nicolson M., Staten M., de Courten M., Moore J., et al. Serum leptin concentration, obesity and insulin resistance in Western Samoans: cross sectional study. BMJ 1996, 313(7063):965-969.
76. Huang X.D., Fan Y., Zhang H., Wang P., Yuan J.P., Li M.J., et al. Serum leptin and soluble leptin receptor in non-alcoholic fatty liver disease. World J Gastroenterol 2009, 14(18):2888-2893.
77. Curat C.A., Miranville A., Sengenes C., Diehl M., Tonus C., Busse R., et al. From blood monocytes to adipose tissue-resident macrophages: induction of diapedesis by human mature adipocytes. Diabetes 2004, 53:1285-1292.
78. Gruen M.L., Hao M.M., Piston D.W., Hasty A.H. Leptin requires canonical migratory signalling pathways for induction of monocyte and macrophage chemotaxis. Am J Physiol Cell Physiol 2007, 293:C1481-C1488.
79. Fernandez-Riejos P., Najib S., Santos-Alvarez J., Martin-Romero C., Perez-Perez A., Gonzalez-Yanes C., et al. Role of leptin in the activation of immune cells. Mediat Inflamm 2010, 2010:568343. 10.1155/2010/568343.
80. Chen C., Chang Y.C., Liu C.L., Liu T.P., Chang K.J., Guo I.C. Leptin induces proliferation and anti-apoptosis in human hepatocarcinoma cells by up-regulating cyclin D1 and down-regulating Bax via a Janus kinase 2-linked pathway. Endocr Relat Cancer 2007, 14:513-529.
81. Watanabe N., Takai K., Lmai K., Shimizu M., Naiki T., Nagaki M., et al. Increased levels of serum leptin are a risk factor for the recurrence of stage I/II hepatocellular carcinoma after curative treatment. J Clin Biochem Nutr 2011, 49(3):153-158.
82. Scherer P.E., Williams S., Fogliano M., Baldini G. Lodish HFl. A novel serum protein similar to C1q, produced exclusively in adipocytes. J Biol Chem 1995, 270:26746-26749.
83. Arita Y., Kihara S., Ouchi N., Takahashi M., Maeda K., Miyagawa J., et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 1999, 257(1):79-83.
84. Rose D.P., Komninou D., Stephenson G.D. Obesity, adipocytokines, and insulin resistance in breast cancer. Obes Rev 2004, 5:153-165.
85. Tajtakova M., Petrasova D., Petrovicova J., Pytliak M., Semanova Z. Adiponectin as a biomarker of clinical manifestation of metabolic syndrome. Endocr Regul 2006, 10(1):15-19.
86. Alikasifoglu A., Gonc N., Ozon Z.A., Sen Y., Kandemir N. The relationship between serum adiponectin, tumor necrosis factor-alpha, leptin levels and insulin sensitivity in childhood and adolescent obesity: adiponectin is a marker of metabolic syndrome. J Clin Res Pediatr Endocrinol 2009, 1(5):233-239.
87. Duggan C., Irwin M.L., Xiao L., Henderson K.D., Smith A.W., Baumgartner R.N., et al. Associations of insulin resistance and adiponectin with mortality in women with breast cancer. J Clin Oncol 2011, 29(1):32-39.
88. Gulcelik M.A., Colakoglu K., Dincer H., Dogan L., Yenidogan E., Gulcelik N.E. Association between adiponectin and two different cancers: breast and colon. Asian Pac J Cancer Prev 2012, 13(1):395-398.
89. Lira F.S., Rosa J.C., Pimentel G.D., Seelaender M., Damaso A.R., Oyama L.M., et al. Both adiponectin and iterleukin-10 inhibit LPS-induced activation of the NF-κB pathway in 3T3-L1 adipocytes. Cytokine 2012, 57(1):98-106.
90. Sharma D., Wang J., Fu P.P., Sharma S., Nagalingam A., Mells J., et al. Adiponectin antagonizes the oncogenic actions of leptin in hepatocellular carcinogenesis. Hepatology 2010, 52(5):1713-1722.
91. Saxena N.K., Fu P.P., Nagalingam A., Wang J., Handy J., Cohen J., et al. Adiponectin modulates C-jun N-terminal kinase and mammalian target of rapamycin and inhibits hepatocellular carcinoma. Gastroenterology 2010, 139(5):1762-1773.
92. Chen M.J., Yeh Y.T., Lee K.T., Tsai C.J., Lee H.H., Wang S.N. The promoting effect of adiponectin in hepatocellular carcinoma. J Surg Oncol 2012, 106(2):181-187.
93. Sadik N.A., Ahmed A., Ahmed S. The significance of serum levels of adiponectin, leptin, and hyaluronic acid in hepatocellular carcinoma of cirrhotic and noncirrhotic patients. Hum Exp Toxicol 2012, 31(4):311-321.
94. Sumie S., Kawaquchi T., Kuromatsu R., Takata A., Nakano M., Satani M., et al. Total and high molecular weight adiponectin and hepatocellular carcinoma with HCV infection. PloS ONE 2011, 6(11):e26840.
95. Park H.S., Park J.Y., Yu R. Relationship of obesity and visceral adiposity with serum concentrations of CRP, TNF-alpha and IL-6. Diab Res Clin Pract 2005, 69(1):29-35.
96. Khaodhiar L., Ling P.R., Blackburn G.L., Bistrian B.R. Serum levels of interleukin-6 and C-reactive protein correlate with body mass index across the broad range of obesity. JPEN J Parenter Enteral Nutr 2004, 28(6):410-415.
97. Popko K., Gorska E., Stelmaszczyk-Emmel A., Plywaczewski R., Stoklosa A., Gorecka D., et al. Proinflammatory cytokines IL-6 and TNF-α and the development of inflammation in obese subjects. Eur J Med Res 2010, 15(Suppl. 2):120-122.
98. Tilg H., Moschen A.R. Evolution of inflammation in non-alcoholic fatty liver disease: the multiple parallel hits hypothesis. Hepatology 2010, 52(5):1836-1846.
99. Carswell E.A., Old L.J., Kassel R.L., Green S., Fiore N., Williamson B. An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci USA 1975, 72:3666.
100. Hotamisligil G.S., Shargill N.S., Spiegelman B.M. Adipose expression of tumor necrosis factor-alpha - direct role in obesity-linked insulin resistance. Science 1993, 259:87-91.
101. Dinarello C.A. Proinflammatory cytokines. Chest 2000, 118(2):503-508.
102. Schuerwegh A.J., Dombrecht E.J., Stevens W.J., Van Offel J.F., Bridts C.H., De Clerck L.S. Influence of pro-inflammatory (IL-1 alpha, IL-6, TNA-alpha, IFN-gamma) and anti-inflammatory (IL-4) cytokines on chondrocyte function. Osteoarthr Cartilage 2003, 11(9):681-687.
103. Matsuno H., Yudoh K., Katayama R., Nakazawa F., Uzuki M., Sawai T., et al. The role of TNF-α in the pathogenesis of inflammation and joint destruction in rheumatoid arthritis (RA): a study using a human RA/SCID mouse chimera. Br Soc Rheumatol 2002, 41:329-337.
104. Guadagni F., Ferroni P., Palmirotta R., Portarena I., Formica V., Roselli M. TNF/VEGF cross-talk in chronic inflammation-related cancer initiation and progression: an early target in anticancer therapeutic strategy. In Vivo 2007, 21(2):147-161.
105. Uysal K.T., Wiesbrock S.M., Marino M.W., Hotamisligil G.S. Protection from obesity-induced insulin resistance in mice lacking TNF-α function. Nature 1997, 389:610-614.
106. Hotamisligil G.S. Inflammatory pathways and insulin action. Int J Obesity 2003, 27(Suppl. 3):S53-S55.
107. Borst S.E. The role of TNF-alpha in insulin resistance. Endocrine 2004, 23(2-3):177-182.
108. De Taeye B.M., Novitskaya T., McGuinness O.P., Gleaves L., Medda M., Covington J.W., et al. Macrophage TNF-α contributes to insulin resistance and hepatic steatosis in diet-induced obesity. Am J Physiol Endocrinol Metab 2007, 293:E713-E725.
109. Nohara A., Okada S., Ohshima K., Pessin J.E., Mori M. Cyclin-dependent kinase-5 is a key molecule in tumor necrosis factor-α induced insulin resistance. J Biol Chem 2011, 286(38):33457-33465.
110. Green A., Rumberger J.M., Stuart C.A., Ruhoff M.S. Stimulation of lipolysis by tumour necrosis factor-α in 3T3-L1 adipocytes is glucose dependent: implications for long-term regulation of lipolysis. Diabetes 2004, 53(1):74-81.
111. Zhan S., Rockey D.C. Tumor necrosis factor α stimulates endothelin-1 synthesis in rat hepatic stellate cells in hepatic wound healing through a novel IKK/JNK pathway. Exp Cell Res 2011, 317(7):1040-1048.
112. Doyle S.L., Donohoe C.L., Lysaght J., Reynolds J.V. Visceral obesity, metabolic syndrome, insulin resistance and cancer. Proc Nutr Soc 2012, 71:181-189.
113. Fontana L., Eagon J.C., Trujillo M.E., Scherer P.E., Klein S. Visceral fat adipokine secretion is associated with systemic inflammation in obese humans. Diabetes 2007, 56(4):1010-1013.
114. Wieckowska A., Papouchado B.G., Li Z., Lopez R., Zein N.N., Feldstein A.E. Increased hepatic and circulating interleukin-6 levels in human non-alcoholic steatohepatitis. Am J Gastroenterol 2008, 103(6):1372-1379.
115. Zimmermann E., Anty R., Tordjman J., Verrijken A., Gual P., Tran A., et al. C-reactive protein levels in relation to various features of non-alcoholic fatty liver disease among obese patients. J Hepatol 2011, 55(3):660-665.
116. Nagaoka S., Yoshida T., Akiyoshi J., Akiba J., Torimura T., Adachi H., et al. Serum C-reactive protein levels predict survival in hepatocellular carcinoma. Liver Int 2007, 27(8):1091-1097.
117. Cook D.G., Mendall M.A., Whincup P.H., Carey I.M., Ballam L., Morris J.E., et al. C-reactive protein concentration in children: relationship to adiposity and other cardiovascular risk factors. Atherosclerosis 2000, 149:139-150.
118. Marques-Vidal P., Bastardot F., von Kanel R., Paccaud F., Preisiq M., Waeber G., et al. Association between circulating cytokine levels, diabetes and insulin resistance in a population-based sample (CoLaus study). Clin Endocrinol (Oxf) 2013, 78(2):232-241.
119. Yang Q., Graham T.E., Mody N., Preitner F., Peroni O.D., Zabolotny J.M., et al. Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes. Nature (Lond) 2005, 436:356-362.
120. Wolf G. Serum retinol-binding protein: a link between obesity, insulin resistance, and type 2 diabetes. Nutr Rev 2007, 65:251-256.
121. Aeberli I., Biebinger R., Lehmann R., L'allemand D., Spinas G.A., Zimmermann M.B. Serum retinol-binding protein 4 concentration and its ratio to serum retinol are associated with obesity and metabolic syndrome components in children. J Clin Endocrinol Metab 2007, 92:4359-4365.
122. Voeltz G.K., Rolls M.M., Rapoport T.A. Structural organization of the endoplasmic reticulum. EMBO Rep 2002, 3(10):944-950.
123. Pahl H.L., Baeuerle P.A. The ER-overload response: activation of NF-kappa B. Trends Biochem Sci 1997, 22(2):63-67.
124. Boden G. Endoplasmic reticulum stress: another link between obesity and insulin resistance/inflammation?. Diabetes 2009, 58(3):518-519.
125. Gregor M.F., Hotamisligil G.S. Adipocyte stress: the endoplasmic reticulum and metabolic disease. J Lipid Res 2007, 48:1905-1914.
126. Kawasaki N., Asada R., Saito A., Kanemoto S., Imaizumi K. Obesity-induced endoplasmic reticulum stress causes chronic inflammation in adipose tissue. Sci Rep 2012, 2:799.
127. Cho H., Wu M., Zhang L., Thompson R., Nath A., Chan C. Signaling dynamics of palmitate-induced ER stress responses mediated by ATF4 in HepG2 cells. BMC Syst Biol 2013, 7:9.
128. Lee J.S., Mendez R., Heng H.H., Yang Z.Q., Zhang K. Pharmacological ER stress promotes hepatic lipogenesis and lipid droplet formation. Am J Transl Res 2012, 4(1):102-113.
129. Snel M., Jonker J.T., Schoones J., Lamb H., de Roos A., Pijl H., et al. Ectopic fat and insulin resistance: pathophysiology and effect of diet and lifestyle interventions. Int J Endicrinol 2012, 2012:983814. 10.1155/2012/983814.
130. Ozcan U., Cao Q., Yilmaz E., Lee A.H., Iwakoshi N.N., Ozdelen E., et al. Endoplasmic reticulum stress links obesity, insulin action, and type 2 diabetes. Science 2004, 306(5695):457-461.
131. Sharma N.K., Das S.K., Mondal A.K., Hackney O.G., Chu W.S., Kern P.A., et al. Endoplasmic reticulum stress markers are associated with obesity in nondiabetic subjects. J Clin Endocrinol Metab 2008, 93(11):4532-4541.
132. Gregor M.F., Yang L., Fabbrini E., Mohammed B.S., Eagon J.C., Hotamisligil G.S., et al. Endoplasmic reticulum stress is reduced in tissues of obese subjects after weight loss. Diabetes 2009, 58(3):693-700.
133. Dhillon A.S., Hagan S., Rath O., Kolch W. MAP kinase signalling pathways in cancer. Oncogene 2007, 26(22):3279-3290.
134. Demchenko Y.N., Kuehl W.M. A critical role for the NFκB pathway in multiple myeloma. Oncotarget 2011, 1(1):59-68.
135. Yu H., Pardoll D., Jove R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer 2009, 9:798-809.
136. Huang B., Zhao J., Unkeless J.C., Feng Z.H., Xiong H. TLR signalling by tumour and immune cells: a double-edged sword. Oncogene 2008, 27:218-224.
137. Baffy G., Brunt E.M., Caldwell S.H. Hepatocellular carcinoma in non-alcoholic fatty liver disease: an emerging menace. J Hepatol 2012, 56(6):1384-1391.
138. He G., Karin M. NF-B and STAT3 - key players in liver inflammation and cancer. Cell Res 2011, 21:159-168.
139. Trayhurn P., Wood I.S. Adipokines: inflammation and the pleiotropic role of white adipose tissue. Br J Nutr 2004, 92:347-355.
140. Kim K.W., Bae S.K., Lee O.H., Bae M.H., Lee M.J., Park B.C. Insulin-like growth factor II induced by hypoxia may contribute to angiogenesis of human hepatocellular carcinoma. Cancer Res 1998, 58(2):348-351.
141. Von Marschall Z., Cramer T., Hocker M., Finkenzeller G., Wiedenmann B., Rosewicz S. Dual mechanism of vascular endothelial growth factor upregulation by hypoxia in human hepatocellular carcinoma. Gut 2001, 48(1):87-96.
142. Li S., Yao D., Wang L., Wu W., Qiu L., Yao M., et al. Expression characteristics of hypoxia-inducible factor-1a and its clinical values in diagnosis and prognosis of hepatocellular carcinoma. Hepat Mon 2011, 11(10):821-828.
143. Wang G.L., Semenza G.L. General involvement of hypoxia-inducible factor 1 in transcriptional response to hypoxia. Proc Natl Acad Sci USA 1993, 90:4304-4308.
144. Semenza G.L. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 2003, 3:721-732.
145. Jiang C., Qu A., Matsubara T., Chanturiya T., Jou W., Gavrilova O., et al. Disruption of hypoxia-inducible factor 1 in adipocytes improves insulin sensitivity and decreases adiposity in high-fat diet-fed mice. Diabetes 2011, 60(10):2484-2495.
146. Bhogal R.H., Curbishley S.M., Weston C.J., Adams D.H., Afford S.C. Reactive oxygen species mediate human hepatocyte injury during hypoxia/reoxygenation. Liver Transpl 2010, 16(11):1303-1313.
147. Fernandez-Sanchez A., Madrigal-Santillan E., Bautista M., Esquivel-Soto J., Morales-Gonzalez A., Esquivel-Chirino C., et al. Inflammation, oxidative stress, and obesity. Int J Mol Sci 2011, 12(5):3117-3132.
148. Karin M. NF-κB as a critical link between inflammation and cancer. Cold Spring Harb Perspect Biol 2009, 1(5):a000141. 10.1101/cshperspect.a000141.
149. Luedde T., Schwabe R.F. NF-κB in the liver-linking injury, fibrosis and hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol 2011, 8(2):108-118.
150. DiDonato J.A., Mercurio F., Karin M. NF-κB and the link between inflammation and cancer. Immunol Rev 2012, 246(1):379-400.
151. Schutze S., Wiegmann K., Machleidt T., Kronke M. TNF-induced activation of NF-kappaB. Immunobiology 1995, 193(2-4):193-203.
152. Garcia M.A., Gallego P., Campagna M., Gonzalez-Santamaria J., Martinez G., Marcos-Villar L., et al. Activation of NF-κB pathway by virus infection requires Rb expression. PLoS ONE 2009, 4(7):e6422. 10.1371/journal.pone.0006422.
153. Li N., Karin M. Is NF-kappaB the sensor of oxidative stress?. FASEB J 1999, 13(10):1137-1143.
154. Ozes O.N., Mayo L.D., Gustin J.A., Pfeffer S.R., Pfeffer L.M., Donner D.B. NF-kappaB activation by tumour necrosis factor requires the Akt serine-threonine kinase. Nature 1999, 401(6748):82-85.
155. Bubici C., Papa S., Pham C.G., Zazzeroni F., Franzoso G. The NF-kappaB-mediated control of ROS and JNK signalling. Histol Histopathol 2006, 21(1):69-80.
156. Shen H.M., Liu Z.G. JNK signalling pathway is a key modulator in cell death mediated by reactive oxygen and nitrogen species. Free Radic Biol Med 2006, 40(6):928-939.
157. Takeda K., Noguchi K., Shi W., Tanaka T., Matsumoto M., Yoshida N., et al. Targeted disruption of the mouse Stat3 gene leads to early embryonic lethality. Proc Natl Acad Sci USA 1997, 94:3801-3804.
158. Lee H., Herrmann A., Deng J.H., Kujawski M., Niu G., Li Z.W., et al. Persistently activated STAT3 maintains constitutive NFκB activity in tumours. Cancer Cell 2009, 15(4):283-293.
159. Wang G.L., Lakova P., Wilde M., Awad S., Timchenko N.A. Liver tumours escape negative control of proliferation via PI3/Akt-mediated block of C/EBP alpha growth inhibitory activity. Genes Dev 2004, 18(8):912-925.
160. Kaido T., Oe H., Imamura M. Interleukin-6 augments hepatocyte growth factor-induced liver regeneration; involvement of STAT3 activation. Hepatogastroenterology 2004, 51(60):1667-1670.
161. Bell L.N., Ward J.L., Degawa-Yamauchi M., Bovenkerk J.E., Jones R., Cacucci B.M., et al. Adipose tissue production of hepatocyte growth factor contributes to elevated serum HGF in obesity. Am J Physiol Endocrinol Metab 2006, 291(4):E843-848.
162. Liu Y., Fuchs J., Li C.L., Lin J.Y. IL-6, a risk factor for hepatocellular carcinoma: FLLL32 inhibits IL-6-induced STAT3 phosphorylation in human hepatocellular cancer cells. Landes Biosci (Cell Cycle) 2010, 9(17):3423-3427.
163. He G., Yu G.Y., Temkin V., Ogata H., Kuntzen C., Sakurai T., et al. Hepatocyte IKK/NF-κB inhibits tumour promotion and progression by preventing oxidative stress-driven STAT3 activation. Cancer Cell 2010, 17:286-297.
164. Schmidt C.M., McKillop I.H., Cahill P.A., Sitzmann J.V. Increased MAPK expression and activity in primary human hepatocellular carcinoma. Biochem Biophys Res Commun 1997, 236(1):54-58.
165. Maeda S. NF-κB, JNK, and TLR signalling pathways in hepatocarcinogenesis. Gastroenterol Res Pract 2010, 2010:367694. 10.1155/2010/367694.
166. Hirosumi J., Tuncman G., Chang L., Gorgun C.Z., Uysal K.T., Maeda K., et al. A central role for JNK in obesity and insulin resistance. Nature 2002, 420(6913):333-336.
167. Hsieh Y.H., Wu T.T., Huang C.Y., Hsieh Y.S., Hwang J.M., Liu J.Y. P38 mitogen-activated protein kinase pathway is involved in protein kinase Ca-regulated invasion in human hepatocellular carcinoma cells. Cancer Res 2007, 67:4320.
168. Hui L., Zatloukal K., Scheuch H., Stepniak E., Wagner E.F. Proliferation of human HCC cells and chemically induced mouse liver cancers requires JNK1-dependent p21 downregulation. J Clin Invest 2008, 118(12):3943-3953.
169. Sears R., Leone G., DeGregori J., Nevins J.R. Ras enhances Myc protein stability. Mol Cell 1999, 3:169-179.
170. Suganami T., Ogawa Y. Adipose tissue macrophages: their role in adipose tissue remodelling. 2010, 88(1):33-39.
171. Chait A., Kim F. Saturated fatty acids and inflammation: who pays the toll?. Arterioscher, Throm Vasc Biol 2010, 30:692-693.
172. Nguyen M.T.A., Favelyukis S., Nguyen A., Reichart D., Scott P.A., Jenn A., et al. A subpopulation of macrophages infiltrates hypertrophic adipose tissue and is activated by free fatty acids via toll-like receptors 2 and 4 and JNK-dependent pathways. JBC 2007, 282(48):35279-35292.
173. Suganami T., Tanimoto-Koyama K., Nishida J., Itoh M., Yuan X., Mizuarai S., et al. Role of the toll-like receptor 4/NF-kappaB pathway in saturated fatty acid-induced inflammatory changes in the interaction between adipocytes and macrophages. Arterioscler Thromb Vasc Biol 2007, 27(1):84-91.
174. Nishimura M., Naito S. Tissue-specific mRNA expression profiles of human toll-like receptors and related genes. Biol Pharm Bull 2005, 28:886-892.
175. Lawless M.W., Greene C.M. Toll-like receptor signalling in liver disease: ER stress the missing link?. Cytokine 2012, 59(2):195-202.
176. Miura K., Seki E., Ohnishi H., Brenner D.A. Role of toll-like receptors and their downstream molecules in the development of non-alcoholic fatty liver disease. Gastroenterol Res Pract 2010, 2010:362847. 10.1155/2010/362847.
177. So E.Y., Ouchi T. The application of Toll like receptors for cancer therapy. Int J Biol Sci 2010, 6(7):675-681.
178. Liu L., Cao Y., Chen C., Zhang X., McNabola A., Wilkie D., et al. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumour angiogenesis, and induces tumour cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res 2006, 66(24):11851-11858.
179. Feng Y.X., Wang T., Deng Y.Z., Yang P., Li J.J., Guan D.X., et al. Sorafenib suppresses postsurgical recurrence and metastasis of hepatocellular carcinoma in an orthotopic mouse model. Hepatology 2011, 53(2):483-492.
180. Lachenmayer A., Toffanin S., Cabellos L., Alsinet C., Hoshida Y., Villanueva A., et al. Combination therapy for hepatocellular carcinoma: additive preclinical efficacy of the HDAC inhibitor panobinostat with sorafenib. J Hepatol 2012, 56(6):1343-1350.
181. Buurman R., Gurlevik E., Schaffer V., Eilers M., Sandbothe M., Kreipe H., et al. Histone deacetylases activate hepatocyte growth factor signalling by repressing microRNA-449 in hepatocellular carcinoma cells. Gastroenterology 2012, 143(3):811-820. E1-15.
182. Jiao P., Ma J., Feng B., Zhang H., Diehl J.A., Chin Y.E., et al. FFA-induced adipocyte inflammation and insulin resistance: involvement of ER stress and IKKβ pathways. Obesity 2011, 19:483-491.
183. Yang J.S., Kim J.T., Jeon J., Park H.S., Kang G.H., Park K.S., et al. Changes in hepatic gene expression upon oral administration of Taurine-conjugated ursodeoxycholic acid in ob/ob mice. PloS ONE 2010, 5(11):e13858.
184. Lim S.C., Choi J.E., Kang H.S., Han S.I. Ursodeoxycholic acid switches oxaliplatin-induced necrosis to apoptosis by inhibiting reactive oxygen species production and activating p53-caspase 8 pathway in HepG2 hepatocellular carcinoma. Int J Cancer 2010, 126(7):1582-1595.
185. Kouchiwa T., Wada K., Uchiyama M., Kasezawa N., Niisato M., Murakami H., et al. Age-related changes in serum amino acids concentrations in healthy individuals. Clin Chem Lab Med 2012, 50(5):861-870.
186. Gentile C.L., Nivala A.M., Gonzales J.C., Pfaffenbach K.T., Wang D., Wei Y., et al. Experimental evidence for therapeutic potential of taurine in the treatment of non-alcoholic fatty liver disease. Am J Physiol Regul Integr Comp Physiol 2011, 301(6):R1710-1722.
187. Sidera K., Gaitanou M., Stellas D., Matsas R., Patsavoudi E. A critical role for HSP90 in cancer cell invasion involves interaction with the extracellular domain of HER-2. J Biol Chem 2008, 283:2031-2041.
188. Stingl L., Stuhmer T., Chatterjee M., Jensen M.R., Flentje M., Djuzenova C.S. Novel HSP90 inhibitors, NVP-AUY922 and NVP-BEP800, radiosensitise tumour cells through cell-cycle impairment, increased DNA damage and repair protraction. Br J Cancer 2010, 102:1578-1591.
189. Tommasi S., Pinto R., Pilato B., Paradiso A. Molecular pathways and related target therapies in liver carcinoma. Curr Pharm Des 2007, 13:3279-3287.
190. Duan S.Q., Venkatraman S., Hong X.C., Huang K., Ulysse L., Mobele B.I., et al. Process development and scale-up of an Hsp90 inhibitor. Org Process Res Dev 2012, 16(11):1787-1793.
191. Aldana-Masangkay G.I., Sakamoto K.M. The role of HDAC6 in cancer. J Biomed Biotechnol 2011, 2011:875824.